BIT Capital’s Akero Therapeutics AKRO Stock Holding History

BIT Capital’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,261	Closed	-$59.9K	–	106
2025 Q3	$59.9K	Hold	1,261	–	–	﹤0.01%	101
2025 Q2	$67.3K	Sell	1,261 -3,176	-72%	-$144K	﹤0.01%	82
2025 Q1	$180K	Buy	+4,437	New	+$188K	0.02%	99
2023 Q4	–	Sell	-4,276	Closed	-$216K	–	97
2023 Q3	$216K	Hold	4,276	–	–	0.03%	83
2023 Q2	$200K	Buy	4,276 +2,335	+120%	+$107K	0.02%	111
2023 Q1	$74.3K	Sell	1,941 -7,082	-78%	-$316K	0.01%	130
2022 Q4	$494K	Sell	9,023 -8,900	-50%	-$381K	0.1%	80
2022 Q3	$610K	Buy	+17,923	New	+$274K	0.11%	57

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BIT Capital's AKRO Position: Q4 2025 in Review

BIT Capital sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 1,261 shares — an estimated $59.9K sold.

BIT Capital first reported a position in AKRO in Q3 2022 and held it in 8 quarters. The position peaked at $610K in Q3 2022. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

BIT Capital reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
BIT Capital sold 1,261 Akero Therapeutics shares in Q4 2025, an estimated $59.9K.
BIT Capital first reported a position in Akero Therapeutics in Q3 2022 and held it in 8 quarters.
BIT Capital's Akero Therapeutics position peaked at $610K in Q3 2022.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on BIT Capital's 13F filing for Q4 2025, filed 11 Feb 2026.